Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study-Reference-Cited by-同舟云学术

Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study

Published:2023-01 Issue:1 Volume:29 Page:60.e1-60.e4
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Fowler Nathan Hale,Dickinson Michael,Ghosh Monalisa^ORCID,Chen Andy I.,Andreadis Charalambos^ORCID,Tiwari Ranjan,Masood Aisha,Ramos Roberto,Jousseaume Etienne,Thieblemont Catherine,Dreyling Martin,Schuster Stephen J.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference14 articles.

1. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5);Mounier;Lancet Haematol,2015

2. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study;Link;Br J Haematol,2019

3. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial;Fowler;Nat Med,2022

4. Efficacy of tisagenlecleucel in adult patients with high-risk relapsed/refractory follicular lymphoma: subgroup analysis of the phase II ELARA study;Thieblemont,2021

5. Tisagenlecleucel therapy: nursing considerations for the outpatient setting;Cunningham;Semin Oncol Nurs,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study;Oncohematology;2024-09-02

2. Mobilizing CARs: Benefits, Drawbacks, and Directions for Outpatient CAR T-cell therapy;Seminars in Hematology;2024-08

3. The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy;Frontiers in Oncology;2024-06-05

4. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update;Blood;2024-04-25

5. CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS;Mediterranean Journal of Hematology and Infectious Diseases;2024-01-01